Increased  ||| S:0 E:10 ||| JJ
risk  ||| S:10 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
lichen  ||| S:18 E:25 ||| JJ
simplex  ||| S:25 E:33 ||| JJ
chronicus  ||| S:33 E:43 ||| NN
in  ||| S:43 E:46 ||| IN
people  ||| S:46 E:53 ||| NNS
with  ||| S:53 E:58 ||| IN
anxiety  ||| S:58 E:66 ||| NN
disorder ||| S:66 E:74 ||| NN
:  ||| S:74 E:76 ||| :
a  ||| S:76 E:78 ||| DT
nationwide  ||| S:78 E:89 ||| JJ
population-based  ||| S:89 E:106 ||| JJ
retrospective  ||| S:106 E:120 ||| JJ
cohort  ||| S:120 E:127 ||| NNS
study  ||| S:127 E:133 ||| VBP
The  ||| S:133 E:137 ||| DT
cingulate  ||| S:137 E:147 ||| JJ
cortex  ||| S:147 E:154 ||| NN
is  ||| S:154 E:157 ||| VBZ
the  ||| S:157 E:161 ||| DT
main  ||| S:161 E:166 ||| JJ
area  ||| S:166 E:171 ||| NN
in  ||| S:171 E:174 ||| IN
the  ||| S:174 E:178 ||| DT
brain  ||| S:178 E:184 ||| NN
involved  ||| S:184 E:193 ||| VBN
in  ||| S:193 E:196 ||| IN
pruritus  ||| S:196 E:205 ||| JJ
processing  ||| S:205 E:216 ||| NN
and  ||| S:216 E:220 ||| CC
is  ||| S:220 E:223 ||| VBZ
deactivated  ||| S:223 E:235 ||| VBN
after  ||| S:235 E:241 ||| IN
scratching ||| S:241 E:251 ||| NN
.  ||| S:251 E:253 ||| .
Lichen  ||| S:253 E:260 ||| FW
simplex  ||| S:260 E:268 ||| FW
chronicus  ||| S:268 E:278 ||| FW
( ||| S:278 E:279 ||| -LRB-
LSC ||| S:279 E:282 ||| NNP
)  ||| S:282 E:284 ||| -RRB-
is  ||| S:284 E:287 ||| VBZ
a  ||| S:287 E:289 ||| DT
common  ||| S:289 E:296 ||| JJ
pruritic  ||| S:296 E:305 ||| JJ
skin  ||| S:305 E:310 ||| NN
disorder  ||| S:310 E:319 ||| NN
characterized  ||| S:319 E:333 ||| VBN
by  ||| S:333 E:336 ||| IN
skin  ||| S:336 E:341 ||| NN
lichenification  ||| S:341 E:357 ||| VBZ
following  ||| S:357 E:367 ||| VBG
excessive  ||| S:367 E:377 ||| JJ
scratching ||| S:377 E:387 ||| NN
.  ||| S:387 E:389 ||| .
Psychological  ||| S:389 E:403 ||| JJ
factors  ||| S:403 E:411 ||| NNS
may  ||| S:411 E:415 ||| MD
contribute  ||| S:415 E:426 ||| VB
to  ||| S:426 E:429 ||| TO
both  ||| S:429 E:434 ||| PDT
the  ||| S:434 E:438 ||| DT
development  ||| S:438 E:450 ||| NN
and  ||| S:450 E:454 ||| CC
persistence  ||| S:454 E:466 ||| NN
of  ||| S:466 E:469 ||| IN
LSC ||| S:469 E:472 ||| NNP
.  ||| S:472 E:474 ||| .
To  ||| S:474 E:477 ||| TO
estimate  ||| S:477 E:486 ||| VB
the  ||| S:486 E:490 ||| DT
hazard  ||| S:490 E:497 ||| NN
ratio  ||| S:497 E:503 ||| NN
( ||| S:503 E:504 ||| -LRB-
HR ||| S:504 E:506 ||| NNP
)  ||| S:506 E:508 ||| -RRB-
of  ||| S:508 E:511 ||| IN
LSC  ||| S:511 E:515 ||| NNP
in  ||| S:515 E:518 ||| IN
people  ||| S:518 E:525 ||| NNS
with  ||| S:525 E:530 ||| IN
anxiety  ||| S:530 E:538 ||| NN
disorders  ||| S:538 E:548 ||| NNS
compared  ||| S:548 E:557 ||| VBN
with  ||| S:557 E:562 ||| IN
the  ||| S:562 E:566 ||| DT
general  ||| S:566 E:574 ||| JJ
population ||| S:574 E:584 ||| NN
.  ||| S:584 E:586 ||| .
In  ||| S:586 E:589 ||| IN
this  ||| S:589 E:594 ||| DT
nationwide  ||| S:594 E:605 ||| JJ
population-based  ||| S:605 E:622 ||| JJ
retrospective  ||| S:622 E:636 ||| JJ
cohort  ||| S:636 E:643 ||| JJ
study  ||| S:643 E:649 ||| NN
we  ||| S:649 E:652 ||| PRP
identified  ||| S:652 E:663 ||| VBD
a  ||| S:663 E:665 ||| DT
total  ||| S:665 E:671 ||| NN
of  ||| S:671 E:674 ||| IN
69 386  ||| S:674 E:681 ||| CD
people ||| S:681 E:687 ||| NNS
,  ||| S:687 E:689 ||| ,
who  ||| S:689 E:693 ||| WP
formed  ||| S:693 E:700 ||| VBD
the  ||| S:700 E:704 ||| DT
anxiety  ||| S:704 E:712 ||| NN
cohort ||| S:712 E:718 ||| NN
,  ||| S:718 E:720 ||| ,
by  ||| S:720 E:723 ||| IN
using  ||| S:723 E:729 ||| VBG
the  ||| S:729 E:733 ||| DT
Taiwan  ||| S:733 E:740 ||| NNP
National  ||| S:740 E:749 ||| NNP
Health  ||| S:749 E:756 ||| NNP
Insurance  ||| S:756 E:766 ||| NNP
Research  ||| S:766 E:775 ||| NNP
Database  ||| S:775 E:784 ||| NNP
from  ||| S:784 E:789 ||| IN
2000  ||| S:789 E:794 ||| CD
to  ||| S:794 E:797 ||| TO
2009 ||| S:797 E:801 ||| CD
.  ||| S:801 E:803 ||| .
The  ||| S:803 E:807 ||| DT
comparison  ||| S:807 E:818 ||| NN
cohort  ||| S:818 E:825 ||| NNS
was  ||| S:825 E:829 ||| VBD
composed  ||| S:829 E:838 ||| VBN
of  ||| S:838 E:841 ||| IN
randomly  ||| S:841 E:850 ||| RB
selected  ||| S:850 E:859 ||| VBN
people  ||| S:859 E:866 ||| NNS
frequency  ||| S:866 E:876 ||| VBP
matched  ||| S:876 E:884 ||| VBN
for  ||| S:884 E:888 ||| IN
age  ||| S:888 E:892 ||| NN
( ||| S:892 E:893 ||| -LRB-
within  ||| S:893 E:900 ||| IN
5-year  ||| S:900 E:907 ||| CD
intervals ||| S:907 E:916 ||| NNS
) ||| S:916 E:917 ||| -RRB-
,  ||| S:917 E:919 ||| ,
sex  ||| S:919 E:923 ||| NN
and  ||| S:923 E:927 ||| CC
index  ||| S:927 E:933 ||| NN
date  ||| S:933 E:938 ||| NN
( ||| S:938 E:939 ||| -LRB-
the  ||| S:939 E:943 ||| DT
date  ||| S:943 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
anxiety  ||| S:951 E:959 ||| NN
diagnosis ||| S:959 E:968 ||| NN
)  ||| S:968 E:970 ||| -RRB-
based  ||| S:970 E:976 ||| VBN
on  ||| S:976 E:979 ||| IN
a  ||| S:979 E:981 ||| DT
1  ||| S:981 E:983 ||| NNP
: ||| S:983 E:984 ||| :
 2  ||| S:984 E:987 ||| CD
ratio ||| S:987 E:992 ||| NN
.  ||| S:992 E:994 ||| .
The  ||| S:994 E:998 ||| DT
risk  ||| S:998 E:1003 ||| NN
of  ||| S:1003 E:1006 ||| IN
LSC  ||| S:1006 E:1010 ||| NNP
was  ||| S:1010 E:1014 ||| VBD
estimated  ||| S:1014 E:1024 ||| VBN
as  ||| S:1024 E:1027 ||| IN
HRs  ||| S:1027 E:1031 ||| JJ
and  ||| S:1031 E:1035 ||| CC
95 ||| S:1035 E:1037 ||| CD
%  ||| S:1037 E:1039 ||| NN
confidence  ||| S:1039 E:1050 ||| NN
intervals  ||| S:1050 E:1060 ||| NNS
( ||| S:1060 E:1061 ||| -LRB-
CIs ||| S:1061 E:1064 ||| NNP
)  ||| S:1064 E:1066 ||| -RRB-
using  ||| S:1066 E:1072 ||| VBG
the  ||| S:1072 E:1076 ||| DT
Cox  ||| S:1076 E:1080 ||| NNP
proportional  ||| S:1080 E:1093 ||| VBD
hazards  ||| S:1093 E:1101 ||| JJ
model ||| S:1101 E:1106 ||| NN
.  ||| S:1106 E:1108 ||| .
After  ||| S:1108 E:1114 ||| IN
adjusting  ||| S:1114 E:1124 ||| VBG
for  ||| S:1124 E:1128 ||| IN
age ||| S:1128 E:1131 ||| NN
,  ||| S:1131 E:1133 ||| ,
sex  ||| S:1133 E:1137 ||| NN
and  ||| S:1137 E:1141 ||| CC
LSC-associated  ||| S:1141 E:1156 ||| JJ
comorbidities ||| S:1156 E:1169 ||| NN
,  ||| S:1169 E:1171 ||| ,
the  ||| S:1171 E:1175 ||| DT
people  ||| S:1175 E:1182 ||| NNS
with  ||| S:1182 E:1187 ||| IN
anxiety  ||| S:1187 E:1195 ||| NN
had  ||| S:1195 E:1199 ||| VBD
a  ||| S:1199 E:1201 ||| DT
1·41-fold  ||| S:1201 E:1211 ||| CD
greater  ||| S:1211 E:1219 ||| JJR
risk  ||| S:1219 E:1224 ||| NN
of  ||| S:1224 E:1227 ||| IN
developing  ||| S:1227 E:1238 ||| VBG
LSC  ||| S:1238 E:1242 ||| NNS
compared  ||| S:1242 E:1251 ||| VBN
with  ||| S:1251 E:1256 ||| IN
the  ||| S:1256 E:1260 ||| DT
people  ||| S:1260 E:1267 ||| NNS
in  ||| S:1267 E:1270 ||| IN
the  ||| S:1270 E:1274 ||| DT
comparison  ||| S:1274 E:1285 ||| NN
cohort  ||| S:1285 E:1292 ||| NNS
( ||| S:1292 E:1293 ||| -LRB-
HR  ||| S:1293 E:1296 ||| NNP
1·41 ||| S:1296 E:1300 ||| NNP
,  ||| S:1300 E:1302 ||| ,
95 ||| S:1302 E:1304 ||| CD
%  ||| S:1304 E:1306 ||| NN
CI  ||| S:1306 E:1309 ||| NNP
1·30-1·52 ||| S:1309 E:1318 ||| NNP
,  ||| S:1318 E:1320 ||| ,
P   ||| S:1320 E:1322 ||| CD
< ||| S:1322 E:1323 ||| SYM
 0·0001 ||| S:1323 E:1330 ||| CD
) ||| S:1330 E:1331 ||| -RRB-
.  ||| S:1331 E:1333 ||| .
In  ||| S:1333 E:1336 ||| IN
particular ||| S:1336 E:1346 ||| JJ
,  ||| S:1346 E:1348 ||| ,
individuals  ||| S:1348 E:1360 ||| NNS
with  ||| S:1360 E:1365 ||| IN
obsessive-compulsive  ||| S:1365 E:1386 ||| JJ
disorder  ||| S:1386 E:1395 ||| NN
had  ||| S:1395 E:1399 ||| VBD
a  ||| S:1399 E:1401 ||| DT
significantly  ||| S:1401 E:1415 ||| RB
increased  ||| S:1415 E:1425 ||| VBN
risk  ||| S:1425 E:1430 ||| NN
of  ||| S:1430 E:1433 ||| IN
developing  ||| S:1433 E:1444 ||| VBG
LSC  ||| S:1444 E:1448 ||| NNP
( ||| S:1448 E:1449 ||| -LRB-
HR  ||| S:1449 E:1452 ||| NNP
1·72 ||| S:1452 E:1456 ||| NNP
,  ||| S:1456 E:1458 ||| ,
95 ||| S:1458 E:1460 ||| CD
%  ||| S:1460 E:1462 ||| NN
CI  ||| S:1462 E:1465 ||| NNP
1·03-2·88 ||| S:1465 E:1474 ||| NNP
,  ||| S:1474 E:1476 ||| ,
P = 0·0395 ||| S:1476 E:1486 ||| CD
) ||| S:1486 E:1487 ||| -RRB-
.  ||| S:1487 E:1489 ||| .
This  ||| S:1489 E:1494 ||| DT
study  ||| S:1494 E:1500 ||| NN
demonstrates  ||| S:1500 E:1513 ||| VBZ
that  ||| S:1513 E:1518 ||| IN
having  ||| S:1518 E:1525 ||| VBG
an  ||| S:1525 E:1528 ||| DT
anxiety  ||| S:1528 E:1536 ||| NN
disorder  ||| S:1536 E:1545 ||| NN
is  ||| S:1545 E:1548 ||| VBZ
associated  ||| S:1548 E:1559 ||| VBN
with  ||| S:1559 E:1564 ||| IN
an  ||| S:1564 E:1567 ||| DT
increased  ||| S:1567 E:1577 ||| JJ
risk  ||| S:1577 E:1582 ||| NN
of  ||| S:1582 E:1585 ||| IN
LSC ||| S:1585 E:1588 ||| NNP
.  ||| S:1588 E:1590 ||| .
Psychological  ||| S:1590 E:1604 ||| JJ
factors  ||| S:1604 E:1612 ||| NNS
were  ||| S:1612 E:1617 ||| VBD
found  ||| S:1617 E:1623 ||| VBN
to  ||| S:1623 E:1626 ||| TO
contribute  ||| S:1626 E:1637 ||| VB
to  ||| S:1637 E:1640 ||| TO
LSC ||| S:1640 E:1643 ||| NNP
.  ||| S:1643 E:1645 ||| .
We  ||| S:1645 E:1648 ||| PRP
recommend  ||| S:1648 E:1658 ||| VBP
combining  ||| S:1658 E:1668 ||| VBG
the  ||| S:1668 E:1672 ||| DT
management  ||| S:1672 E:1683 ||| NN
of  ||| S:1683 E:1686 ||| IN
LSC  ||| S:1686 E:1690 ||| NNP
and  ||| S:1690 E:1694 ||| CC
psychological  ||| S:1694 E:1708 ||| JJ
disorders  ||| S:1708 E:1718 ||| NNS
to  ||| S:1718 E:1721 ||| TO
achieve  ||| S:1721 E:1729 ||| VB
favourable  ||| S:1729 E:1740 ||| JJ
outcomes ||| S:1740 E:1748 ||| NNS
.  ||| S:1748 E:1750 ||| .
